Literature DB >> 11774281

Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer.

Yih-Lin Chung1, Meei-Ling Sheu, Shun-Chun Yang, Chi-Hung Lin, Sang-Hue Yen.   

Abstract

Overexpression of Her2/neu is implicated in the development of resistance to the antiestrogen tamoxifen (TAM) that exerts its inhibitory effect through interaction with estrogen receptor (ER). Whereas Her2/neu and ER are believed to be important cell survival/death factors in human breast cancer cells, if and how they interact to confer resistance to hormone therapy is not known. This prompted us to investigate whether modulation of the effect of TAM occurs via the Her2/neu pathway and whether targeting the interaction between the Her2/neu pathway and the ER pathway is beneficial. There are 2 forms of ER that are localized to the cell membrane and to the nucleus. For the first time, we found that Her2/neu directly interacts with ER at the cell membrane. We then investigated the role of Her2/neu overexpression in the regulation of the cell membrane ER pathway in TAM-resistant breast cancer cells and the nature of this interaction in apoptotic signaling. Relief of TAM resistance was associated with Her2/neu downregulation and ER upregulation. TAM-induced apoptosis occurred immediately after dissociation of Her2/neu from cell membrane ER. These results demonstrate a novel mechanism by which Her2/neu regulates the cell membrane ER-coupled apoptosis and the possible involvement of the Her2/neu in TAM resistance of breast cancer cells. Moreover, the antiproliferative activity of TAM should rely on the integration between the signal transduction from the cell membrane ER and the gene regulation by the nuclear ER. Coordinated modulation on the cell membrane ER/Her2/neu pathway and the nuclear ER/RAR pathway may provide a new approach for treatment of ER-positive, Her2/neu overexpressing breast cancer. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11774281     DOI: 10.1002/ijc.1614

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  39 in total

Review 1.  Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies.

Authors:  Weimin Fan; Jinjia Chang; Peifeng Fu
Journal:  Future Med Chem       Date:  2015-08-26       Impact factor: 3.808

2.  Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.

Authors:  C Giordano; S Catalano; S Panza; D Vizza; I Barone; D Bonofiglio; L Gelsomino; P Rizza; S A W Fuqua; S Andò
Journal:  Oncogene       Date:  2011-04-18       Impact factor: 9.867

Review 3.  The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance.

Authors:  Cynthie Wong; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2012-01-08       Impact factor: 4.292

4.  Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancer.

Authors:  Benjamin M Larimer; Susan L Deutscher
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-08-15

Review 5.  Minireview: The Link Between ERα Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer.

Authors:  Stéphanie Légaré; Mark Basik
Journal:  Mol Endocrinol       Date:  2016-07-20

Review 6.  Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications.

Authors:  Mario Giuliano; Meghana V Trivedi; Rachel Schiff
Journal:  Breast Care (Basel)       Date:  2013-08       Impact factor: 2.860

7.  Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.

Authors:  Sarah Croessmann; Luigi Formisano; Lisa N Kinch; Paula I Gonzalez-Ericsson; Dhivya R Sudhan; Rebecca J Nagy; Aju Mathew; Eric H Bernicker; Massimo Cristofanilli; Jie He; Richard E Cutler; Alshad S Lalani; Vincent A Miller; Richard B Lanman; Nick V Grishin; Carlos L Arteaga
Journal:  Clin Cancer Res       Date:  2018-10-12       Impact factor: 12.531

8.  AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.

Authors:  Cynthie Wong; Xin Wang; David Smith; Kaladhar Reddy; Shiuan Chen
Journal:  Breast Cancer Res Treat       Date:  2012-06-16       Impact factor: 4.872

9.  Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells.

Authors:  Cinzia Giordano; Donatella Vizza; Salvatore Panza; Ines Barone; Daniela Bonofiglio; Marilena Lanzino; Diego Sisci; Francesca De Amicis; Suzanne A W Fuqua; Stefania Catalano; Sebastiano Andò
Journal:  Mol Oncol       Date:  2012-11-23       Impact factor: 6.603

10.  Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer.

Authors:  Akriti Kharbanda; Hasan Rajabi; Caining Jin; Deepak Raina; Donald Kufe
Journal:  Mol Cancer Res       Date:  2013-03-28       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.